|21.95|| -1.30 / -5.59%|
Insmed, Inc. operates as a biopharmaceutical company focused on developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. The company is focused on the development and commercialization of ARIKAYCE or liposomal amikacin for inhalation (LAI), for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Its main product ARIKAYCE or LAI, is a once-a-day inhaled antibiotic treatment engineered to deliver an anti-infective directly to the site of serious lung infections. Insmed was founded on November 29, 1999 and is headquartered in Monmouth Junction, NJ.
|William H. Lewis||President, Chief Executive Officer & Director|
|Andrew T. Drechsler||Chief Financial Officer|
|Walter R. Perkins||Chief Technology Officer|
|Gina Eagle||Vice President-Clinical Research|
|Eugene Jeffrey Sullivan||Chief Medical & Scientific Officer|